Should a 45-year-old premenopausal woman with a 1.8 cm grade 1 hormone‑receptor‑positive, HER2‑negative, node‑negative invasive ductal carcinoma, Recurrence Score 18, who has already completed four cycles of docetaxel‑carboplatin, be given additional chemotherapy?

No Additional Chemotherapy Should Be Given

This patient has already received more chemotherapy than necessary and should proceed directly to endocrine therapy with ovarian function suppression. 1

Rationale

Chemotherapy Was Not Indicated in the First Place

For this clinical scenario—a premenopausal woman with:

• 1.8 cm, grade 1 tumor
• Node-negative
• HR+/HER2-negative
• Recurrence Score 18

The patient falls into a low-to-intermediate risk category where chemotherapy benefit is minimal to absent. The TAX316 trial that established docetaxel-based regimens in breast cancer specifically studied node-positive disease 2, which this patient does not have. The FDA label for docetaxel in adjuvant breast cancer explicitly states it is for "axillary-node-positive breast cancer" 2.

Four Cycles Already Exceeds Standard Requirements

Even if chemotherapy were indicated (which it was not), the patient has completed four cycles of docetaxel-carboplatin. Standard adjuvant regimens are:

• TAC (docetaxel/doxorubicin/cyclophosphamide): 6 cycles 2
• TC (docetaxel/cyclophosphamide): 4 cycles 3

The patient has already received a complete course by TC standards.

The Real Treatment Priority: Endocrine Therapy with OFS

The critical intervention this patient needs is aggressive endocrine therapy, not more chemotherapy. 1

Given her young age (45 years, premenopausal) and the fact she received chemotherapy, she meets criteria for ovarian function suppression (OFS) plus aromatase inhibitor:

• Exemestane + OFS for 5 years is the evidence-based regimen 1
• The TEXT-SOFT trials demonstrated superior disease-free survival with AI + OFS versus tamoxifen + OFS in premenopausal women (HR 0.77,95% CI 0.67-0.90) 1
• The ASTRRA trial confirmed benefit in women <45 years who received chemotherapy (8-year DFS: 85.4% with tamoxifen + OFS vs 80.2% with tamoxifen alone, HR 0.67) 1

Critical Considerations for Recurrence Score 18

While RS 18 falls in the intermediate range, grade 1 histology is a powerful favorable prognostic factor that modifies risk assessment in premenopausal women 4. Recent evidence shows that in younger patients with intermediate RS (11-25), high-grade tumors drive recurrence risk—this patient has grade 1 disease 4.

Research specifically addressing low RS (1-18) in node-negative disease shows excellent prognosis with endocrine therapy alone, with recurrences primarily occurring in patients who failed to comply with endocrine therapy 5. This underscores that adherence to endocrine therapy is more important than additional chemotherapy in this population.

Common Pitfalls to Avoid

1. Do not reflexively add chemotherapy based on premenopausal status alone—the benefit comes from OFS, not chemotherapy, in this risk category
2. Do not use tamoxifen alone—this patient qualifies for intensified endocrine therapy with OFS based on age and chemotherapy receipt
3. Ensure patient understands the critical importance of endocrine therapy adherence—this is where treatment failure occurs in this population 5

Recommended Treatment Plan

1. Stop chemotherapy immediately—no additional cycles
2. Initiate OFS with GnRH agonist (goserelin or leuprolide) 1
3. Start exemestane 25 mg daily (or alternative AI: anastrozole or letrozole) 1
4. Continue for 5 years 1
5. Counsel extensively on adherence—this is the most important intervention for preventing recurrence in this patient 5